Sutent

(Sunitinib)

Phase 3Small molecule

Sunitinib is used to treat certain types of cancer, including kidney cancer and gastrointestinal tumors. It works by blocking proteins that help cancer cells grow and divide.[1] Sutent is currently being investigated across 18 indications[3], with its most advanced program in Phase 3.[1]

Sutent is one of 401 small molecule programs targeting Thymic Carcinoma. It is currently in Phase 3.

Indications

381

Total Trials

Active Trials

400

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thymic CarcinomaUnknown status

Advanced Solid TumorsCompleted

Neuroendocrine NeoplasmUnknown

Renal Cell CarcinomaCompleted

MortalityActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Advanced LymphomaActive, not recruiting

GliomaActive, not recruiting

OsteosarcomaRecruiting

Gastrointestinal Stromal TumorCompleted

Thymic CarcinomaPhase 2

Unknown status

Advanced Solid TumorsPhase 2

Completed

Neuroendocrine NeoplasmPreclinical

Unknown

Renal Cell CarcinomaPhase 3

Completed

MortalityPreclinical

Active, not recruiting

Mantle Cell LymphomaPreclinical

Active, not recruiting

Advanced LymphomaPhase 2

Active, not recruiting

GliomaPreclinical

Active, not recruiting

OsteosarcomaPhase 2

Recruiting

Gastrointestinal Stromal TumorPhase 3

Completed

Showing 10 of 18 indications

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

51 2

Taxol

Teva

Phase 2

25 3

Opdivo

Bristol-Myers Squibb

Phase 2

19 4

Sutent

Pfizer

Phase 3

3 5

Paraplatin

AAvyxa

Phase 2

32 6

Tecentriq

Roche

Phase 2

11 7

Beyfortus

BeiGene

Phase 2

10 8

Taxotere

AAvyxa

Phase 2

23 9

Yervoy

Bristol-Myers Squibb

Phase 2

6 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

GIST

NCT05245968

Phase 1/2Recruiting

Solid Tumors

NCT05024214

Phase 3Active, not recruiting

Treatment

NCT03673501

Phase 2Active, not recruiting

Uveal Melanoma

NCT02068586

Q1 2027

Phase 2Recruiting

Trial

NCT03297606

Q4 2027

Phase 2Recruiting

Trial

NCT02925234

Clinical

Trials by Indication[1]

Renal Cell Carcinoma42 trials

Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma

Terminated·AAmsterdam UMC, location VUmc·Phase 2·NCT02071641·5 enrolled

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 3·NCT00720941·1,110 enrolled

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

Completed·SSpanish Oncology Genito-Urinary Group··NCT03519542·62 enrolled

Show 39 more trials

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Completed· Novartis logo

Novartis·Phase 2·NCT01147822·367 enrolled

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Completed·—·Phase 2·NCT01108445·131 enrolled

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT01391130·110 enrolled

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00975806·16 enrolled

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT02398552·80 enrolled

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

Completed· Pfizer logo

Pfizer··NCT04076787·1,769 enrolled

Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT01070186

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Terminated·IIndiana University·N/A·NCT01502228·14 enrolled

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

Completed· Pfizer logo

Pfizer··NCT05745142·376 enrolled

Sequential Study to Treat Renal Cell Carcinoma

Completed·SSponsor GmbH·Phase 3·NCT00732914·272 enrolled

Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT00930345·33 enrolled

Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing

Completed·—·Phase 2·NCT03109015·7 enrolled

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Completed·SStanford University·N/A·NCT00537056·17 enrolled

Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma

Unknown status·—·Phase 2·NCT01219751·35 enrolled

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Terminated·—·Phase 1·NCT03905889·3 enrolled

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT00556049·72 enrolled

SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT00089648·61 enrolled

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Withdrawn·GGuru Sonpavde·Phase 2·NCT03035630

A Study for Participants With Metastatic Renal Cell Carcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00709995·17 enrolled

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02853331·861 enrolled

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed· Roche logo

Roche·Phase 2·NCT01984242·305 enrolled

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 3·NCT02535351·13 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed· Roche logo

Roche·Phase 3·NCT02420821·915 enrolled

Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT03066427·23 enrolled

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02231749·1,390 enrolled

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT06032728·488 enrolled

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Completed·AArgos Therapeutics·Phase 2·NCT00678119·25 enrolled

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01472081·194 enrolled

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Completed·MMendus·Phase 2·NCT02432846·88 enrolled

Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02060370·60 enrolled

Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

Completed·CCentre Leon Berard·Phase 2·NCT00619268·160 enrolled

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Completed· Pfizer logo

Pfizer··NCT04175262·102 enrolled

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

Completed·—·Phase 1·NCT00788060·5 enrolled

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

Completed· Amgen logo

Amgen·Phase 2·NCT00853372·85 enrolled

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Completed·IImmatics Biotechnologies GmbH·Phase 3·NCT01265901·339 enrolled

A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Not yet recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·N/A·NCT02688491·300 enrolled

A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Terminated·UUniversity Health Network, Toronto·Phase 2·NCT00480935·3 enrolled

Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients

Completed·KKidney Cancer Research Bureau·Phase 1/2·NCT00891475·114 enrolled

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

Withdrawn·AAndrea Harzstark·Phase 2·NCT01616186

Breast Cancer7 trials

Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00291577·22 enrolled

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00471276·83 enrolled

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT00417885·6 enrolled

Show 4 more trials

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Completed· Pfizer logo

Pfizer·Phase 1·NCT00372424·26 enrolled

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00373256·488 enrolled

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00482755·4 enrolled

Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00824538·13 enrolled

Kidney Cancer6 trials

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT01064310·169 enrolled

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

Completed·—·Phase 2·NCT00459979·30 enrolled

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 2·NCT02960906·200 enrolled

Show 3 more trials

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Completed·—··NCT01026337·43 enrolled

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01061411·16 enrolled

Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer

Completed·RRoswell Park Cancer Institute·N/A·NCT00849186·20 enrolled

Treatment6 trials

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Completed· Pfizer logo

Pfizer·N/A·NCT00428220·223 enrolled

Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Completed· Pfizer logo

Pfizer··NCT04669366·1,205 enrolled

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

Completed·ZZai Lab (Shanghai) Co., Ltd.·Phase 2·NCT04633122·108 enrolled

Show 3 more trials

Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)

Completed·—··NCT04368546·6 enrolled

Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01621568·56 enrolled

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Active, not recruiting·DDeciphera Pharmaceuticals, LLC·Phase 3·NCT03673501·453 enrolled

Gastric Cancer5 trials

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Completed·SSamsung Medical Center·Phase 2·NCT03170180·66 enrolled

Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI

Completed·PPD Dr Markus Möhler·Phase 2·NCT01020630·91 enrolled

An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

Completed· Pfizer logo

Pfizer·Phase 2·NCT00226811·78 enrolled

Show 2 more trials

Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00553696·27 enrolled

Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer

Completed·JJohannes Gutenberg University Mainz·Phase 2·NCT00411151·52 enrolled

86 more indications

Non-Small Cell Lung Cancer5 trials

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Completed· Pfizer logo

Pfizer·Phase 3·NCT00457392·960 enrolled

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01306045·647 enrolled

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00113516·84 enrolled

Show 2 more trials

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

Completed· Pfizer logo

Pfizer·Phase 2·NCT00265317·162 enrolled

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00698815·130 enrolled

Pancreatic Neuroendocrine Tumor4 trials

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer·Phase 4·NCT01525550·106 enrolled

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer·Phase 2·NCT01121562·12 enrolled

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer··NCT02282059·100 enrolled

Show 1 more trial

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT02713763·11 enrolled

Prostate Cancer4 trials

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00676650·873 enrolled

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00631527·19 enrolled

Multimodality Phase II Study in Prostate Cancer

Terminated·—·Phase 2·NCT00734851·36 enrolled

Show 1 more trial

An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00748358·50 enrolled

Glioblastoma4 trials

Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma

Completed·MMassachusetts General Hospital·Phase 1·NCT00864864·8 enrolled

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Withdrawn·CCenter Trials & Treatment·Phase 1·NCT03275558

Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients

Completed·GGrupo Español de Investigación en Neurooncología·Phase 2·NCT01100177·12 enrolled

Show 1 more trial

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

Unknown status·BBassam Abdulkarim·Phase 2·NCT02928575·45 enrolled

Metastatic Renal Cell Cancer3 trials

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Terminated· Roche logo

Roche·Phase 2·NCT00491738·16 enrolled

A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01829841·150 enrolled

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

Completed·UUniversity of Utah·Phase 1·NCT00694096·25 enrolled

Metastatic3 trials

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Terminated·TThe Methodist Hospital Research Institute·Phase 1/2·NCT00522249·10 enrolled

A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

Terminated·AAVEO Pharmaceuticals, Inc.·Phase 2·NCT01673386·58 enrolled

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

Unknown status·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT03592199·7 enrolled

Metastatic Colorectal Cancer3 trials

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00457691·768 enrolled

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00609622·191 enrolled

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00806663·22 enrolled

Phase II3 trials

Phase II Study of Alternating Sunitinib and Temsirolimus

Completed·—·Phase 2·NCT01517243·37 enrolled

Phase II Sunitinib Prog Met AIPC

Completed·UUS Oncology Research·Phase 2·NCT00599313·36 enrolled

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00434109·39 enrolled

Melanoma3 trials

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

Withdrawn·—·Phase 2·NCT02400385

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00482911·12 enrolled

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Completed·—·Phase 2·NCT00577382·52 enrolled

Advanced Solid Tumors3 trials

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

Recruiting·RRabin Medical Center·Phase 1/2·NCT06940349·100 enrolled

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Completed·CCogent Biosciences, Inc.·Phase 1/2·NCT02401815·51 enrolled

Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors

Completed·JJaime Merchan·Phase 1·NCT00884676·36 enrolled

Trial3 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Gastrointestinal Stromal Tumor3 trials

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Unknown status·SShanghai Zhongshan Hospital·N/A·NCT03862768·92 enrolled

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Active, not recruiting·CCogent Biosciences, Inc.·Phase 3·NCT05208047·442 enrolled

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00372567·69 enrolled

Advanced Cancer2 trials

Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer

Completed· Pfizer logo

Pfizer·Phase 1·NCT00712504·49 enrolled

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02483247·165 enrolled

Unresectable2 trials

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT02230176·84 enrolled

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

Completed·—·Phase 1·NCT02164240·14 enrolled

Refractory Solid Tumors2 trials

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Completed·SSamsung Medical Center·N/A·NCT02450123·1 enrolled

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Completed·SSamsung Medical Center·Phase 4·NCT02691793·1 enrolled

Cancer2 trials

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

Unknown status·UUniversity Medical Center Groningen·Phase 4·NCT05949424·30 enrolled

The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients

Completed·LLeiden University Medical Center·Phase 1·NCT01743300·15 enrolled

Renal Cell Cancer2 trials

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02560012·4 enrolled

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00465179·61 enrolled

Gastrointestinal Stromal Tumour2 trials

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04409223·185 enrolled

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Completed·AAB Science·Phase 3·NCT01694277·258 enrolled

Uveal Melanoma2 trials

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Completed·TThe Clatterbridge Cancer Centre NHS Foundation Trust·Phase 2·NCT01551459·124 enrolled

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02068586·210 enrolled

Paraganglioma2 trials

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00843037·25 enrolled

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01371201·78 enrolled

Patients With Solid Tumors2 trials

Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

Completed·AAmsterdam UMC, location VUmc·Phase 1·NCT02058901·101 enrolled

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT00599924·53 enrolled

Small Cell Lung Cancer2 trials

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00695292·37 enrolled

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

Completed·NNational Cancer Center, Korea·Phase 2·NCT00620347·25 enrolled

Bevacizumab2 trials

Bevacizumab in Multiple Phase I Combinations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543504·343 enrolled

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Completed· Amgen logo

Amgen·Phase 1·NCT00861419·88 enrolled

Neuroendocrine Tumors2 trials

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02315625·16 enrolled

Treatment With SU11248 in Patients With Neuroendocrine Tumors

Completed· Pfizer logo

Pfizer·Phase 2·NCT00056693·107 enrolled

Glioblastoma Multiforme2 trials

SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme

Unknown status·MMedical University Innsbruck·Phase 2·NCT00535379·70 enrolled

A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme

Unknown status·AAmsterdam UMC, location VUmc·Phase 2/3·NCT03025893·100 enrolled

Patients With Advanced Solid Tumors2 trials

Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00729833·45 enrolled

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT01286896·43 enrolled

Thymic Carcinoma2 trials

Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03449173·56 enrolled

A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT02623127·25 enrolled

Efficacy and Safety2 trials

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT04394975·421 enrolled

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00373113·482 enrolled

Effectiveness2 trials

Cost Effectiveness Of Sunitinib In Central America And Caribbean

Terminated· Pfizer logo

Pfizer··NCT01033981·4 enrolled

Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland

Completed·PPirkko-Liisa Kellokumpu-Lehtinen··NCT00980213·80 enrolled

Advanced Solid Malignancies2 trials

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01636908·43 enrolled

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Completed· Pfizer logo

Pfizer·Phase 1·NCT00732992·12 enrolled

Dacarbazine1 trial

A Phase I/II Study of Sunitinib and Dacarbazine

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00496223·11 enrolled

Chemotherapy1 trial

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 1/2·NCT00783653·22 enrolled

Clear Cell Renal Cancer1 trial

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

Terminated·AAssociació per a la Recerca Oncologica, Spain·Phase 2·NCT01784978·41 enrolled

Advanced1 trial

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Active, not recruiting·DDeciphera Pharmaceuticals, LLC·Phase 3·NCT05734105·54 enrolled

GIST1 trial

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Active, not recruiting· Taiho Pharmaceutical Co., Ltd. logo

Taiho Pharmaceutical Co., Ltd.·Phase 1·NCT05245968·78 enrolled

Protein Kinase Inhibitors1 trial

Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors

Unknown status·UUniversity Hospital, Grenoble·N/A·NCT03571438·100 enrolled

Efficacy1 trial

To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.

Unknown status·PPeking University··NCT03424876·60 enrolled

Esophageal Cancer1 trial

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00400114·36 enrolled

Liver Cancer1 trial

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00247676·37 enrolled

AIN1 trial

Sutent Maintenance After Response to Taxotere

Unknown status·AAlberta Health services·Phase 2·NCT00550810·30 enrolled

Tics1 trial

An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers

Completed·UUniversity of Cologne·Phase 1·NCT00904657·12 enrolled

Alveolar Soft Part Sarcoma1 trial

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01391962·34 enrolled

Bladder Cancer1 trial

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00847015·18 enrolled

Maintenance Therapy1 trial

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00616109·16 enrolled

Central Nervous System1 trial

Sunitinib in Sarcomas of the Central Nervous System

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT03641326·5 enrolled

Clear Cell Renal Carcinoma1 trial

Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00979966·22 enrolled

Colorectal Cancer1 trial

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00668863·71 enrolled

First Line Therapy1 trial

Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

Terminated· Pfizer logo

Pfizer··NCT03140176·77 enrolled

Solid Tumors1 trial

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Recruiting·33D Medicines (Sichuan) Co., Ltd.·Phase 1/2·NCT05024214·170 enrolled

Urothelial Cancer1 trial

Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer

Unknown status·CCampania Younger Oncologists Association·Phase 1/2·NCT00818350·25 enrolled

Osteosarcoma1 trial

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07477457·45 enrolled

Ovarian Clear Cell Carcinoma1 trial

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Completed·—·Phase 2·NCT01824615·30 enrolled

Peritoneal Carcinoma1 trial

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Completed·—·Phase 2·NCT00768144·36 enrolled

Ascites1 trial

Trial of Sunitinib for Refractory Malignant Ascites

Terminated·MMilton S. Hershey Medical Center·Phase 2·NCT00796861·4 enrolled

Glioma1 trial

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Unknown status·AAmsterdam UMC, location VUmc·N/A·NCT02239952·15 enrolled

Advanced Cancers1 trial

Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

Completed·UUniversity of Chicago·Phase 1·NCT00583063·23 enrolled

ctDNA1 trial

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Recruiting·UUniversity of Miami·Phase 2·NCT05366816·48 enrolled

Cholangiocarcinoma1 trial

A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01718327·53 enrolled

Tumour1 trial

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Completed·AAB Science·Phase 2·NCT01506336·44 enrolled

Triple-Negative Breast Cancer1 trial

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00887575·54 enrolled

Carcinoma1 trial

Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy

Completed·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT00663559·59 enrolled

Advanced Solid Tumor1 trial

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00495872·204 enrolled

Adenoid Cystic Carcinoma1 trial

A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00886132·14 enrolled

Ablation1 trial

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01254864·190 enrolled

Mantle Cell Lymphoma1 trial

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Completed· Pfizer logo

Pfizer··NCT00700258·1,520 enrolled

Thyroid Cancer1 trial

Thyroid Cancer and Sunitinib

Completed·UUniversity Hospital, Bordeaux·Phase 2·NCT00510640·71 enrolled

Interaction1 trial

To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib

Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 1·NCT01548170·12 enrolled

Radiotherapy1 trial

Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy

Completed·CCentre Leon Berard·Phase 1·NCT01308034·25 enrolled

First-line1 trial

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

Completed· Pfizer logo

Pfizer··NCT04115189·57 enrolled

Lung Adenocarcinoma1 trial

Sunitinib in Never-Smokers With Lung Adenocarcinoma

Completed·—·Phase 2·NCT01829217·13 enrolled

Pembrolizumab1 trial

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Completed· Incyte logo

Incyte·Phase 3·NCT03260894·129 enrolled

GEP-NET1 trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting·RRayzeBio, Inc.·Phase 3·NCT05477576·288 enrolled

Locally Advanced1 trial

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05043090·148 enrolled

Advanced Biliary Tract Carcinoma1 trial

Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma

Completed·SSamsung Medical Center·Phase 2·NCT01082809·59 enrolled

Prostatectomy1 trial

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00329043·64 enrolled

Gastroesophageal Junction1 trial

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00891878·12 enrolled

Soft Tissue Sarcoma1 trial

Sunitinib in Certain Subtypes of Soft Tissue Sarcomas

Terminated·—·Phase 2·NCT00859456·10 enrolled

Acute Lymphoblastic Leukemia1 trial

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT01620216·12 enrolled

Transitional Cell Carcinoma1 trial

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Completed·—·Phase 2·NCT01089088·63 enrolled

Leiomyosarcoma1 trial

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00378911·44 enrolled

Pancreatic Cancer1 trial

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00397787·64 enrolled

Ovarian Cancer1 trial

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00979992·35 enrolled

Endometrial Cancer1 trial

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00478426·34 enrolled

Islet Cell Tumor1 trial

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00428597·171 enrolled

Safety and Efficacy1 trial

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene

Completed· Pfizer logo

Pfizer··NCT00444795·520 enrolled

Unspecified2 trials

Rollover Protocol for Prior SU011248 Protocols

Completed· Pfizer logo

Pfizer·N/A·NCT00798889·314 enrolled

Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 2·NCT01168440·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 381 trial records for Sunitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sunitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sunitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Macrophage Colony Stimulating Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Alpha Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer